IDH2 and central nervous system cancer: Mutations of isocitrate dehydrogenase 1 (IDH1) and rarely of isocitrate dehydrogenase 2 (IDH2), are driver mutations of low-grade glioma and secondary glioblastoma (GBM)13,14 and associated with both seizures and better outcome.